Tiziana Life Sciences plc: PDMR Dealing
20 Outubro 2021 - 3:00AM
Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS)
("
Tiziana" or the "
Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation and infectious diseases, today announces
that it has been notified that Panetta Partners Limited, an entity
in which Gabriele Cerrone, the Executive Chairman has a beneficial
interest, purchased 60,000 ordinary shares of 3p each in the market
at a price of 55p per share.
The acquisition takes Mr Cerrone's interests
from 34.208% to 34.238% (within the 1% incremental threshold under
Note 11 to Rule 9 of the UK Takeover Code).
1. |
Details of PDMR / person closely associated |
a) |
Name |
Gabriele Cerrone |
2. |
Reason for the notification |
a) |
Position / status |
Chairman |
b) |
Initial notification /amendment |
Initial notification |
3. |
Details of the issuer |
a) |
Name |
Tiziana Life Sciences plc |
b) |
LEI |
213800CED47HI8PIOB36 |
4. |
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument |
Ordinary Shares of 3p each |
b) |
Identification code of the Financial Instrument |
ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 |
c) |
Nature of the transaction |
Market Purchase |
d) |
Price(s) and volume(s) |
55p 60,000 |
f) |
Date of the transaction |
4 October 2021 |
g) |
Place of the transaction |
XLON |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed
(NASDAQ:TLSA, UK LSE: TILS) biotechnology company that focuses on
the discovery and development of novel molecules to treat human
diseases in oncology, inflammation and infectious diseases. In
addition to Milciclib, the Company will be shortly initiating Phase
2 studies with orally administered Foralumab for Crohn's Disease
and nasally administered Foralumab for progressive multiple
sclerosis. Foralumab is the only fully human anti-CD3 monoclonal
antibody ("mAb") in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as Crohn's Disease, multiple
sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease
("IBD"), psoriasis and rheumatoid arthritis, where modulation of a
T-cell response is desirable. The Company is accelerating
development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully
human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
Tiziana Life Sciences
plc |
+44 (0)20 7495
2379 |
Gabriele Cerrone,
Chairman, and founder |
|
|
United
States: |
Investors: |
Dave Gentry,
CEO |
RedChip Companies
Inc. |
407-491-4498 |
dave@redchip.com |
Tiziana Life Sciences (NASDAQ:TLSA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024